Spots Global Cancer Trial Database for waldenström macroglobulinemia

Every month we try and update this database with for waldenström macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia	NCT02844361	Waldenström Mac...	autologous stem... conventional ch...	18 Years - 70 Years	Institute of Hematology & Blood Diseases Hospital, China
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00060294	Lymphoma	rituximab yttrium Y 90 ib...	18 Years -	Jonsson Comprehensive Cancer Center
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00041379	Lymphoma	beta alethine	18 Years -	National Cancer Institute (NCI)
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01812005	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	alisertib rituximab laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis	NCT00132015	Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co...	tanespimycin	18 Years -	National Institutes of Health Clinical Center (CC)
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	NCT00088881	Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... Waldenström Mac...	rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi...	18 Years -	National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	NCT00005786	Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	arsenic trioxid... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma	NCT00608374	Lymphoma	chlorambucil fludarabine pho... quality-of-life...	18 Years -	National Cancer Institute (NCI)
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia	NCT02844322	Waldenström Mac...	Bortezomib Rituximab	18 Years - 85 Years	Institute of Hematology & Blood Diseases Hospital, China
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.	NCT00919139	Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis	biologic sample...	-	SWOG Cancer Research Network
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00003416	Lymphoma	filgrastim recombinant int... dexamethasone melphalan peripheral bloo...	- 69 Years	SWOG Cancer Research Network
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00110071	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai...	60 Years -	Fred Hutchinson Cancer Center
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	NCT00002779	Lymphoma	fludarabine pho... octreotide acet...	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia	NCT03187262	Waldenström Mac...	Daratumumab	18 Years -	Dana-Farber Cancer Institute
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia	NCT00723658	Lymphoma	rituximab bortezomib carmustine cisplatin cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide melphalan thalidomide autologous-auto... peripheral bloo...	18 Years -	SWOG Cancer Research Network
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	NCT02049541	Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00110071	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	fludarabine pho... peripheral bloo... iodine I 131 to... laboratory biom... flow cytometry polymerase chai...	60 Years -	Fred Hutchinson Cancer Center
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia	NCT00723658	Lymphoma	rituximab bortezomib carmustine cisplatin cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide melphalan thalidomide autologous-auto... peripheral bloo...	18 Years -	SWOG Cancer Research Network
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00073918	Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	cyclophosphamid... etoposide iodine I 131 to... quality-of-life... peripheral bloo...	18 Years - 60 Years	Fred Hutchinson Cancer Center
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM	NCT02844309	Waldenström Mac...	Thalidomide	18 Years - 85 Years	Institute of Hematology & Blood Diseases Hospital, China
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00012298	Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab yttrium Y 90 ib... indium In 111 i... oprelvekin filgrastim	18 Years -	National Cancer Institute (NCI)
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	NCT00062244	Waldenström Mac...	oblimersen sodi...	18 Years -	National Cancer Institute (NCI)
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	NCT00621452	B-cell Chronic ... Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	therapeutic aut... cyclophosphamid... aldesleukin polymerase chai... gene rearrangem... lymph node biop... genetically eng... bone marrow asp... flow cytometry laboratory biom... enzyme-linked i...	-	Fred Hutchinson Cancer Center
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	NCT02049541	Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac...	PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00005609	Lymphoma	rituximab	18 Years -	National Cancer Institute (NCI)
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	NCT03833180	Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac...	Zilovertamab ve...	18 Years -	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	NCT00062244	Waldenström Mac...	oblimersen sodi...	18 Years -	National Cancer Institute (NCI)
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia	NCT01536067	Waldenström Mac...	ofatumumab bortezomib laboratory biom...	18 Years -	Roswell Park Cancer Institute
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00020800	Lymphoma	rituximab fludarabine pho...	18 Years -	Jonsson Comprehensive Cancer Center
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia	NCT02844361	Waldenström Mac...	autologous stem... conventional ch...	18 Years - 70 Years	Institute of Hematology & Blood Diseases Hospital, China
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	NCT03833180	Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac...	Zilovertamab ve...	18 Years -	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	NCT00005786	Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	arsenic trioxid... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	NCT00054639	Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	oblimersen sodi... rituximab laboratory biom...	18 Years -	National Cancer Institute (NCI)
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia	NCT02180724	Waldenström Mac...	Acalabrutinib (... Acalabrutinib (...	18 Years - 130 Years	Acerta Pharma BV
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003784	Lymphoma	CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... tositumomab and...	18 Years -	SWOG Cancer Research Network
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00081068	Lymphoma	alemtuzumab	18 Years -	Jonsson Comprehensive Cancer Center
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia	NCT00003416	Lymphoma	filgrastim recombinant int... dexamethasone melphalan peripheral bloo...	- 69 Years	SWOG Cancer Research Network
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia	NCT00281983	Chronic Lymphoc...	alemtuzumab anti-thymocyte ... filgrastim rituximab therapeutic all... busulfan cyclophosphamid... cyclosporine fludarabine pho... methotrexate mycophenolate m... peripheral bloo... radiation thera...	18 Years - 65 Years	German CLL Study Group
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia	NCT02844322	Waldenström Mac...	Bortezomib Rituximab	18 Years - 85 Years	Institute of Hematology & Blood Diseases Hospital, China
FR901228 in Treating Patients With Hematologic Cancer	NCT00024180	Leukemia Lymphoma	romidepsin	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00290472	B-cell Chronic ... Extranodal Marg... Malignant Neopl... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	temsirolimus	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	NCT02213913	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac...	lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom...	18 Years -	University of Chicago
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.	NCT00919139	Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis	biologic sample...	-	SWOG Cancer Research Network
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	NCT00058240	B-cell Chronic ... Recurrent Small... Refractory Chro... Waldenström Mac...	alvocidib	18 Years -	National Cancer Institute (NCI)
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia	NCT00566332	Waldenström Mac... Lymphoplasmacyt... Splenic Margina...	Chlorambucil Fludarabine	18 Years -	French Study Group on Chronic Lymphoid Leukemia
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder	NCT00064246	Post-transplant... Recurrent Adult... Recurrent Adult... Stage III Adult... Stage III Adult... Stage IV Adult ... Stage IV Adult ... Waldenström Mac...	rituximab indium In 111 i... yttrium Y 90 ib...	18 Years -	National Cancer Institute (NCI)
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia	NCT01536067	Waldenström Mac...	ofatumumab bortezomib laboratory biom...	18 Years -	Roswell Park Cancer Institute
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	NCT00058240	B-cell Chronic ... Recurrent Small... Refractory Chro... Waldenström Mac...	alvocidib	18 Years -	National Cancer Institute (NCI)
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers	NCT00003658	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... pentostatin	18 Years -	Memorial Sloan Kettering Cancer Center
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia	NCT00005579	Leukemia Lymphoma	dolastatin 10	18 Years -	National Cancer Institute (NCI)
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00087425	Leukemia Lymphoma	rituximab bryostatin 1	18 Years -	National Cancer Institute (NCI)
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia	NCT02844322	Waldenström Mac...	Bortezomib Rituximab	18 Years - 85 Years	Institute of Hematology & Blood Diseases Hospital, China
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia	NCT00281983	Chronic Lymphoc...	alemtuzumab anti-thymocyte ... filgrastim rituximab therapeutic all... busulfan cyclophosphamid... cyclosporine fludarabine pho... methotrexate mycophenolate m... peripheral bloo... radiation thera...	18 Years - 65 Years	German CLL Study Group
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers	NCT00003658	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... pentostatin	18 Years -	Memorial Sloan Kettering Cancer Center
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	NCT02933320	B-cell Lymphoma Chronic Lymphoc... Waldenström Mac...	BI-1206 single ... Combination of ... BI-1206 single ... Combination of ...	18 Years -	Cancer Research UK
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma	NCT00088881	Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... Waldenström Mac...	rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi...	18 Years -	National Cancer Institute (NCI)
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia	NCT02640287	Waldenström Mac...	Blood or bone m...	18 Years -	Central Hospital, Nancy, France
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia	NCT04463953	Waldenström Mac...	Zanubrutinib,Ix...	18 Years -	Institute of Hematology & Blood Diseases Hospital, China
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: